MKI67 and neoplasm: Subsequent 18F-FDG PET/CT resolved this challenge by identifying hypermetabolic foci (SUVmax 8.5) within the lesion, guiding a repeat biopsy to viable tumor regions that confirmed SMARCA4 loss (BRG1-negative, Ki67 70%).